LC/MS continues to be a platform of considerable importance to the needs of drug discovery and development. Considering the long history of the technique from the first introduction of a liquid into the vacuum of a mass spectrometer to today’s routine (and non-routine) applications, LC/MS has demonstrated a resilience based on practical adaptability. Of course, this is due in no small part to the innovative capabilities of many talented scientists. Not everything has worked out as speculated but the advances in sensitivity, ease of use, reduced footprint and overall capability support high expectations of the future of LC/MS. Such expectations are fueled by the needs of modern disease treatment and it is exciting to see yet more novel and thought-provoking innovations happening at the forefront of LCMS technology development. This presentation will introduce the following symposium on future initiatives and give thought to what may pave the way for another decade or more of progress in LC/MS.
If you asked a bioanalyst 30 years ago what more they wanted from LC/MS the answer was typically “10 x more sensitivity”. Even though that was delivered within 5 years and constant improvements in sensitivity have continued since, if you ask the same question again today it will likely induce the same answer … “more sensitivity”. Today however it comes with some added nuance including sample size, matrix type, portability and application to an ever expanding range of analyte modality. Beyond sensitivity we see some critical needs for addressing the needs of the patient and where associated microsampling techniques continue to evolve. Turnaround time to produce decision enabling data is another area that is attracting a convergence of automation, sample analysis throughput and machine learning data processing. In the regulated bioanalytical space, the guidance and regulations themselves are attempting to keep up with the rapid pace of technology development. All of this presents a fertile ground for innovation to meet the needs. In this respect fit-for-purpose is as relevant a concept for the modern bioanalyst as it has ever been.
The next decade may not have us operating our personal LC/MS system on our wrist as a smart watch but we can expect further evolution and developments that may make us question in the near future what we were thinking of and wrestling with back in 2020.
Upon completion, participants will have added perspective on current and future developments of LC/MS technolgy and application.
Upon completion, participants will be able to reflect on the recent progrees and understand ongoing initiatives to apply LC/MS to new challenges in drug discovery and development.
Upon completion, particpants will be able to join the conversation on leveraging the strenths of LC/MS to further modern bioanalysis.